NervGen Pharma Corp. (NGEN)
1.78
+0.02
(+1.14%)
USD |
NASDAQ |
Oct 02, 16:00
1.82
+0.04
(+2.25%)
After-Hours: 20:00
NervGen Pharma Enterprise Value : 128.24M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 128.24M |
| October 01, 2026 | 126.11M |
| September 30, 2026 | 142.07M |
| September 29, 2026 | 143.14M |
| September 28, 2026 | 138.88M |
| September 25, 2026 | 145.27M |
| September 24, 2026 | 153.78M |
| September 23, 2026 | 147.40M |
| September 22, 2026 | 158.57M |
| September 21, 2026 | 150.59M |
| September 18, 2026 | 156.97M |
| September 17, 2026 | 180.38M |
| September 16, 2026 | 165.49M |
| September 15, 2026 | 166.55M |
| September 14, 2026 | 172.40M |
| September 11, 2026 | 171.34M |
| September 10, 2026 | 168.68M |
| September 09, 2026 | 165.49M |
| September 08, 2026 | 171.87M |
| September 04, 2026 | 186.77M |
| September 03, 2026 | 185.70M |
| September 02, 2026 | 186.77M |
| September 01, 2026 | 185.70M |
| August 31, 2026 | 174.00M |
| August 28, 2026 | 181.45M |
| Date | Value |
|---|---|
| August 27, 2026 | 187.30M |
| August 26, 2026 | 174.00M |
| August 25, 2026 | 160.16M |
| August 24, 2026 | 151.65M |
| August 21, 2026 | 136.75M |
| August 20, 2026 | 126.11M |
| August 19, 2026 | 125.05M |
| August 18, 2026 | 120.79M |
| August 17, 2026 | 117.60M |
| August 14, 2026 | 123.45M |
| August 13, 2026 | 126.11M |
| August 12, 2026 | 126.11M |
| August 11, 2026 | 123.98M |
| August 10, 2026 | 119.73M |
| August 07, 2026 | 120.79M |
| August 06, 2026 | 121.86M |
| August 05, 2026 | 117.60M |
| August 04, 2026 | 115.47M |
| August 03, 2026 | 113.34M |
| July 31, 2026 | 111.22M |
| July 30, 2026 | 109.09M |
| July 29, 2026 | 108.02M |
| July 28, 2026 | 110.15M |
| July 27, 2026 | 113.34M |
| July 24, 2026 | 112.28M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| InMed Pharmaceuticals, Inc. | 4.867M |
| Milestone Pharmaceuticals, Inc. | 72.03M |
| Clearmind Medicine, Inc. | -12.60M |
| Lexaria Bioscience Corp. | 0.8348M |
| Target Group, Inc. (Canada) | 11.59M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.10M |
| Total Expenses (Quarterly) | 21.10M |
| EPS Diluted (Quarterly) | -0.2283 |
| Earnings Yield | -30.11% |
| Normalized Earnings Yield | -19.56 |